References
- Hoster E, Dreyling M, Klapper W, et al. A new prognostic index for patients with advanced stage mantle cell lymphoma. Blood 2008; 111(2):558–565.
- Rummel MJ, Niederle N, Maschmeyer G, et al. Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomaan open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381(9873):1203–1210.
- Kenkre VP, Long WL, Eickhoff JC, et al. Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma 2011; 52(9):1675–1680.
- Bhatt A, Farooq MU, Chang HT. Mantle Cell Lymphoma and Anti-MuSK Positive Myasthenia Gravis. Onkologie 2011; 34:382–383.
- Pedersen EG, Pottegård A, Hallas J, et al. Myasthenia and risk of cancer: a population-based case-control study. Eur J Neurol 2014; 21(5):773–778.
- Levin N, Abramsky O, Lossos A, et al. Extrathymic malignancies in patients with myasthenia gravis. J Neurol Sci 2005; 237(1–2):39–43.
- Abrey LE. Association of myasthenia gravis with extrathymic Hodgkin’s lymphoma: complete resolution of myasthenic symptoms following antineoplastic therapy. Neurology 1995; 45(5):1019.
- Finelli PF. Primary CNS lymphoma in myasthenic on long-term azathioprine. J Neurooncol 2005; 74(1):91–92.
- Vose JM. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 2015; 90(8):739–745.
- Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131(1):29–38.
- Kirkegaard MM, Coupland SE, Prause JU, et al. Malignant lymphoma of the conjunctiva. Surv Ophthalmol 2015; 60(5):444–458.
- Looi A, Gascoyne RD, Chhanabhai M, et al. Mantle cell lymphoma in the ocular adnexal region. Ophthalmology 2005; 112(1):114–119.
- Rasmussen P, Sjӧ LD, Prause JU, et al. Mantle cell lymphoma in the orbital and adnexal region. Br J Ophthalmol 2009; 93(8):1047–1051.
- Verdijk R. An update of ocular adnexal lymphomas. Diagnost Histopathol 2015; 21(1):26–33.
- Middle S, Coupland SE, Taktak A, et al. Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin’s lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins. Exper Hematol Oncol 2015; 4(10):1–11.
- Hwang CJ, Afifiyan N, Sand D, et al. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci 2009; 50(5):2262–2268.
- Liu Z, Dong HY, Gorczyca W, et al. CD5- mantle cell lymphoma. Am J Clin Pathol 2002; 118(2):216–224.
- Tasaki K, Shichishima A, Furuta M, et al. CD5-positive mucosa-associated lymphoid tissue (MALT) lymphoma of ocular adnexal origin: usefulness of fluorescence in situ hybridization for distinction between mantle cell lymphoma and MALT lymphoma. Pathol Int 2007; 57(2):101–107.